FindTrial
Sign In

JNJ-75348780

DRUG5 trials

Sponsors

Janssen-Cilag International NV, Janssen Research & Development, LLC

Conditions

Leukemia, Lymphocytic, Chronic, B-CellLeukemia, Myeloid, AcuteLymphoma, Non-HodgkinMyelodysplastic SyndromesNeoplasmsNon-Hodgkin lymphoma and chronic lymphocytic leukemia CancerProstatic Neoplasms, Castration-ResistantSolid Tumor, Adult

Phase 1

A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
CompletedNCT04540796
Janssen Research & Development, LLCLeukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin
Start: 2020-11-20End: 2025-09-09Updated: 2025-10-10
A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer
Active, not recruitingNCT06139406
Janssen Research & Development, LLCLymphoma, Non-Hodgkin
Start: 2023-12-06End: 2026-08-31Updated: 2026-05-08
A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)
Active, not recruitingNCT06660563
Janssen Research & Development, LLCLymphoma, Non-Hodgkin
Start: 2024-10-22End: 2026-09-21Updated: 2026-05-08
A rollover study for continued study treatment and ongoing safety monitoring
RecruitingISRCTN87946208
Janssen-Cilag International NVNon-Hodgkin lymphoma and chronic lymphocytic leukemia Cancer
Start: 2024-12-31Target: 77Updated: 2025-03-31
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Enrolling by invitationNCT06788509
Janssen Research & Development, LLCLeukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, Non-Hodgkin +4
Start: 2024-12-30End: 2028-10-30Target: 120Updated: 2026-05-08

Related Papers

Characterization of JNJ-80948543 a novel CD79bxCD20xCD3 trispecific antibody for B-cell non-Hodgkin lymphoma.
2026-02-26
JNJ-87801493 (CD20xCD28), a Potential First-in-Class CD20 Targeted CD28 Costimulatory Bispecific Antibody, Enhances the Activity of B-Cell Targeting T-Cell Engagers in Preclinical Models
Blood2024-11-053 citations
ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies
Molecular Cancer Therapeutics2024-02-079 citations